Paul Abrams - Poniard Pharmaceuticals Ex Officer
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Insider
Paul Abrams is Ex Officer of Poniard Pharmaceuticals
| Phone | 206 281 7001 |
| Web | https://www.poniard.com/ |
Poniard Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4603) % which means that it has lost $0.4603 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1037) %, meaning that it created substantial loss on money invested by shareholders. Poniard Pharmaceuticals' management efficiency ratios could be used to measure how well Poniard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Poniard Pharmaceuticals currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Poniard Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Poniard Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Poniard Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poniard Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poniard to invest in growth at high rates of return. When we think about Poniard Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alistair Milnes | Bicycle Therapeutics | 50 | |
| Steven Rice | Vir Biotechnology | 64 | |
| MBA MD | Ikena Oncology | 59 | |
| Chris MBA | Crinetics Pharmaceuticals | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| Kyle Piskel | Adaptive Biotechnologies Corp | 40 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Nitin Sood | Adaptive Biotechnologies Corp | N/A | |
| Mark Adams | Adaptive Biotechnologies Corp | 57 | |
| MBA MBA | Adaptive Biotechnologies Corp | 50 | |
| Marc Harrison | Legend Biotech Corp | N/A | |
| Gillian Langford | Bicycle Therapeutics | N/A | |
| Martin MD | Xilio Development | 63 | |
| Christian Heinis | Bicycle Therapeutics | N/A | |
| MBA MD | Scholar Rock Holding | 57 | |
| Uli Bialucha | Xilio Development | N/A | |
| MBA MPH | Protara Therapeutics | 41 | |
| Johanna FriedlNaderer | Vir Biotechnology | 56 | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Nicholas Keen | Bicycle Therapeutics | 56 | |
| Louis MD | Vir Biotechnology | N/A | |
Management Performance
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 |
Poniard Pharmaceuticals Leadership Team
Elected by the shareholders, the Poniard Pharmaceuticals' board of directors comprises two types of representatives: Poniard Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poniard. The board's role is to monitor Poniard Pharmaceuticals' management team and ensure that shareholders' interests are well served. Poniard Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poniard Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Abrams, Ex Officer | ||
| Robert Caspari, Ex Officer |
Poniard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Poniard Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Number Of Shares Shorted | 47.72 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Net Income | (30.05 M) | ||||
| Cash And Equivalents | 1.98 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets |